How to use this page
I wrote this one for a teenager with psoriasis. It covers school, PE and swimming, your scalp, your mood, and taking over your own care.
Psoriasis in this age group is covered by published guidance. That guidance is what I read before writing what follows.
Strength, amount and course length belong to the person who prescribes for you. Ask for those in the room.
Community ideas are labeled because they vary by person. They are options, not promises about how another person will respond.
Is psoriasis in your teens taken seriously?
Care for your age group is written down. A teenager with psoriasis is not an edge case.
I read the joint guideline the American Academy of Dermatology and the National Psoriasis Foundation publish for psoriasis in children and adolescents. It covers creams, light treatment and systemic medicines.
I checked what NICE assesses: the skin, the nails, high-impact sites, the impact on daily life, and any joint concerns. Your school day counts inside that.
So you can ask a dermatologist what that guidance says for someone your age. It is a fair question to put in the room.
What do you say when someone asks if it is catching?
One short line settles it. Psoriasis is immune-mediated, so nobody can catch it from you.
I read the National Psoriasis Foundation page, which records that an overactive immune system speeds up skin-cell growth. Raised plaques and scale are the visible sign of that.
So a plaque is your own immune system at work. It does not move to a friend in a pool or a changing room.
You do not owe a class a talk about it. One sentence, then a change of subject, is enough.
Sources for the facts above: Evidence
Lived experience - varies by person
PE, swimming, and the changing room
Kit rubs, sweat builds, and a changing room is public. A plan made before the lesson beats a choice made at the door.
I read NIAMS on this: rubbing and sweating can worsen psoriasis in skin folds. The American Academy of Dermatology lists skin injury among flare triggers, naming a cut, a scrape, a scratch and a sunburn.
The AAD also records washing with warm water rather than hot, and using a gentle cleanser made for sensitive skin. It records blotting dry and moisturizing within about five minutes.
So a towel, a fragrance-free moisturizer and a spare top cover most of it. Ask a dermatologist about chlorine and about anything that stings a plaque.
Scalp psoriasis and your hair
People I have heard from describe a scalp that will not clear whatever they try. Scale along a hairline is common enough to have its own guidance, and hair tends to grow back once the scalp clears.
I read the American Academy of Dermatology scalp pages, which record that hair loss sometimes follows when psoriasis develops there. Hair tends to regrow once the scalp psoriasis clears.
They record combing and brushing scale away gently rather than picking, keeping nails short, and using conditioner at every wash. Scratching can cause bleeding and noticeable shedding.
If shedding keeps going, say so at a visit. The AAD records that hair loss can have other causes.
Spots, face products, and your psoriasis treatment
Teenage skin often carries more than one product at once. Tell the prescriber every one of them.
A topical steroid is an anti-inflammatory medicine you put on the skin. I read the American Academy of Dermatology page on them: they cut redness, swelling, scaling and itch.
They run from very mild to extremely strong. A strong one on thin skin such as the face carries skin-thinning, spider-vein and stretch-mark risk.
The National Psoriasis Foundation records the same potency range. It advises checking with a clinician rather than carrying on with a topical steroid without review.
So bring the names of every cream, wash and face product to the visit. Strength, body site and course length stay with the prescriber.
Sources for the facts above: Evidence Evidence Evidence
Ask your care teamWhen your mood takes a hit
Mood and skin get measured together in research, and the numbers are not small. Feeling low about this is not an overreaction.
I read the joint pediatric guideline, which advises screening young people who have psoriasis for related conditions. It names depression and anxiety among them.
A 2010 UK study of family-doctor records found higher rates of noted depression and anxiety among people with psoriasis. A 2015 study across 13 European countries found low mood about twice as common in skin-clinic patients.
Those are patterns across groups, not a forecast for you. If your mood has shifted, say so at the next visit and ask who on the team handles that part.
Lived experience - varies by person
Dating and telling someone
There is no required moment to tell someone, and no required amount of detail.
Some people mention it early so the waiting stops. Others wait until trust builds, or until a covered patch may be seen.
Both routes work. The dating and disclosure guide below takes the same decision further.
Taking over your own care
Knowing your own treatment names comes first. Keeping the record yourself comes next.
I looked at the National Psoriasis Foundation tracker page: tracking symptoms and triggers over time can help you find your own pattern. It says the record can be shared with a provider.
Note what changed, where it changed, and how bad it got. Photos kept in one folder beat memory at the next visit.
The American Academy of Pediatrics advises raising a young person’s part in health decisions as they develop, alongside parental permission.
So asking for part of a visit on your own is a reasonable request. Ask the clinic how they usually arrange that.
Sources for the facts above: Evidence Evidence Evidence
Ask your care teamThe honest limits
Some of this has no clean answer yet, and it helps to know which parts.
- Published guidance for this age group does not pick one best treatment for one person.
- Mood research describes groups of people, so it forecasts nothing about you.
- School rules, PE rules and clinic habits differ, so ask where you are rather than assuming.
- Strength, amount, body site and course length stay with the person who prescribes for you.
Bring to your next visit
You can use these as written or change the words. Saving keeps a question on this device.
What does the pediatric psoriasis guidance say for someone my age, and how does that shape my plan?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which exact products am I on right now, and which body area is each one for?
Saving keeps this on your device and needs JavaScript, which is off in this browser.My scalp sheds and my hair looks thinner. What would you change about my scalp treatment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Can I have part of my appointments on my own, and how does your clinic usually arrange that?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the American Academy of Dermatology (Menter A, Cordoro KM, Davis DMR, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to the author relationships disclosed for the guideline, not to the journal itself.
What this source supports
Supports that the American Academy of Dermatology and the National Psoriasis Foundation share one guideline for psoriasis in children. Supports that it covers topical, light and systemic treatment in that age group. Supports the reported link between guttate psoriasis in a child and strep throat. Supports checking a child who has psoriasis for other health problems. It names low mood and anxiety. It also names extra weight.
What it does not support
It does not judge one child. It names no product, no strength and no course length. It gives no figure for how many children get better. It is US guidance. It sets no coverage rule.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization publishes patient education, but the editorial and funding independence of this page was not separately reviewed.
What this source supports
Supports that psoriasis is an immune-mediated disease. It causes inflammation in the body. Raised plaques and scale on the skin are the visible sign. Supports that an overactive immune system speeds up skin-cell growth. Skin cells normally take about a month to grow and shed. With psoriasis they do so in three or four days. Supports that psoriasis is a chronic, long-term disease with no cure.
What it does not support
Does not predict whether one person will clear, stay the same, or flare. Does not give a share of people who reach a period with little or no psoriasis, or how long such a period lasts. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that poor sleep quality is a listed symptom of psoriasis. Also lists patches of thick, red, scaly skin that itch or burn, and dry, cracked skin that itches or bleeds. Supports that psoriasis carries risk for mental-health concerns including low self-esteem, anxiety, and depression. Supports that managing common triggers, such as stress and skin injuries, can help keep symptoms under control. Supports, by subtype, that guttate psoriasis outbreaks are often triggered by an upper respiratory infection such as strep throat. Also supports that pustular psoriasis symptoms can be triggered by medications, infections, stress, or certain chemicals. Also supports that erythrodermic psoriasis can be triggered by a bad sunburn or certain medications including corticosteroids. Also supports, by subtype, that inverse psoriasis appears as smooth patches of inflamed skin in skin folds. It names the armpits, the groin, and under the breasts as those folds. It records that rubbing and sweating can make inverse psoriasis worse.
What it does not support
Does not give a percentage of patients affected. Does not measure how much sleep is lost. Does not establish that treating the skin fixes the sleep problem for any one person. Its trigger information is organized by psoriasis subtype, not as one general list for plaque psoriasis specifically. It counts nothing for inverse psoriasis either. It gives no share of people affected in a fold or genital site, and it names no treatment for one.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that stress can trigger a psoriasis flare. Supports that skin injury - a cut, scrape, sunburn, tattoo, piercing, bug bite, or shaving nick - can trigger a flare near or at that spot. Typically this appears about 10 to 14 days after the injury. Supports that an infection such as strep throat, an earache, or bronchitis can trigger a flare, reported 2 to 6 weeks later. Supports that starting a medication - including lithium, antimalarial drugs, strong corticosteroids, or some blood pressure drugs - can trigger a flare about 2 to 3 weeks after starting it. Supports that cold, dry weather (such as winter or fall) can worsen flares, and that sunburn or spending time in air conditioning can also worsen them. Supports that smoking, or spending time around secondhand smoke, is a reported trigger. Supports that drinking daily, or more than two drinks on several days a week, can make psoriasis treatment have little or no effect. Supports that triggers differ from person to person.
What it does not support
Does not cite a specific study for its trigger list or timing windows, and does not state how many patients experience each trigger. This page displays no revision date; the date recorded here matches the same AAD psoriasis disease microsite's treatment-and-diagnosis page, checked the same day. Does not establish that avoiding a listed trigger will prevent a flare for any one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bathing once a day, showers of about 5 minutes, and baths of about 15 minutes or less. Supports warm, not hot, water, and a gentle cleanser made for sensitive skin, not a deodorant soap or scrub. Supports washing with hands, not a loofah, buff puff, or washcloth, then rinsing well. Supports blotting skin dry while leaving it a little damp, then applying a fragrance-free moisturizer within about five minutes of finishing.
What it does not support
Does not give a byline or last-reviewed date on the page itself. Does not state how much these steps reduce flares for a given person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that hair loss sometimes follows when psoriasis develops on the scalp. Supports that hair tends to regrow once the scalp psoriasis clears. Supports gently combing and brushing away scale, avoiding picking, and applying treatment directly to the scalp. Supports keeping fingernails short and smooth, alternating medicated and gentle shampoo, using conditioner every wash, and air drying instead of blow-drying. Also supports testing hair products for irritation first, and telling a dermatologist if treatment feels too harsh. Also supports telling a dermatologist if hair loss persists, since it can have other causes.
What it does not support
Does not give a byline or last-reviewed date on the page itself. Does not give a timeframe for regrowth or say every case of hair loss is caused by the psoriasis itself.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports avoiding scratching, which can worsen psoriasis, cause bleeding, and lead to noticeable hair loss. Supports avoiding picking off scale, which can trigger a flare. Supports gentle shampooing rather than vigorous rubbing or scrubbing. Supports a salicylic-acid scale softener before removing scale, and lifting hair out of the way when applying medicine. Supports managing stress, since stress can worsen psoriasis and add to hair shedding.
What it does not support
Does not give a byline or last-reviewed date on the page itself. Does not quantify how much any single habit reduces flares or hair loss.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that topical corticosteroids reduce redness, swelling, scaling and itch, and slow skin-cell growth. They come in strengths from very mild to extremely strong and are typically applied twice daily. Strong products on thin skin such as the face carry skin-thinning, spider-vein and stretch-mark risk. Most people see results with short twice-daily use, and no improvement after four to six weeks is a signal to return to the prescriber.
What it does not support
The page does not display its own separate revision date; the date recorded here matches the same AAD psoriasis treatment section’s dated overview page checked the same day. It does not name potency classes by number, give a percentage of people who improve, or set a maximum course length.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization provides patient education, but its editorial and funding independence for this page was not independently reviewed.
What this source supports
Supports that topical steroids range from super-potent to least potent, and that guidance advises not using one for longer than three weeks without checking with a clinician. Side effects include skin thinning, pigment change, easy bruising, stretch marks, redness and dilated blood vessels. Systemic absorption is a risk with widespread, prolonged or occluded use, and abruptly stopping a topical steroid can cause a psoriasis flare.
What it does not support
It does not name which specific product falls in which potency class, quantify how often a side effect occurs, or set a course length for any specific product or body site.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Archives of Dermatology (Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict notes were not checked beyond the published record. So the status here is set to not established.
What this source supports
Supports that one study used a UK family-doctor database. It tracked more than 145,000 people with psoriasis. It also tracked a much larger group with no psoriasis. Supports a higher rate of noted depression in the psoriasis group. Supports a higher rate of noted anxiety. Supports a higher rate of noted self-harm risk. Supports that the rise in depression showed up in mild psoriasis. Supports that the rise was larger in severe psoriasis.
What it does not support
Does not show that psoriasis causes any of this. Does not judge or predict one person. It counts only what a doctor wrote down. So it misses what was never raised in a visit. It covers one database and one span of years. It does not describe US care today.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of Investigative Dermatology (Dalgard FJ, Gieler U, Tomas-Aragones L)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict notes were not checked beyond the published record. So the status here is set to not established.
What this source supports
Supports that skin-clinic patients in 13 European countries were screened. They were screened for low mood, for worry, and for thoughts of self-harm. A group with no skin problem was screened too. Supports that low mood was about twice as common in the patient group. Supports that worry was more common in the patient group. Supports that thoughts of self-harm were more common there too. Supports that psoriasis was one of the skin problems in the study.
What it does not support
Does not split psoriasis out from the other skin problems. Does not give a figure for psoriasis alone. It looked at people at one point in time. So it cannot show what came first. Does not judge or predict one person. It was run in Europe and does not describe US care today.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that tracking symptoms and common triggers over time can help a person figure out their own specific triggers. Supports naming stress, alcohol, and diet as examples of common triggers to watch for. Supports naming discolored skin patches and itching as psoriasis symptoms, and joint swelling and fatigue as psoriatic arthritis symptoms, to watch for. Supports using a worksheet to record daily symptoms and their severity, and sharing that worksheet with a health care provider.
What it does not support
Does not give a percentage or timeline for how much tracking changes any one outcome. Does not name every possible trigger - stress, alcohol, and diet are examples, not a complete list. Does not measure whether tracking itself helps or burdens a given person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing a symptom tracker, kept on paper or on a phone, to share with a doctor at an appointment. Supports clearly describing symptoms and noting changes in severity and affected areas as part of preparing for a visit.
What it does not support
Does not mention photographing skin changes specifically. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of Pediatrics Committee on BioethicsGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports increasing a child or adolescent’s participation in health decisions in keeping with development, alongside parental permission and professional responsibility.
What it does not support
It is general pediatric ethics guidance, not a SteadySkin minimum-age policy, a jurisdiction-specific consent opinion or evidence for any Vitiligo treatment.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.